Definium Therapeutics (DFTX) Common Equity (2020 - 2026)

Definium Therapeutics (DFTX) has reported Common Equity for 7 consecutive years, with $278.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 25.15% year-over-year to $278.8 million; the TTM figure through Mar 2026 stood at $278.8 million (up 25.15% YoY), while the FY2025 annual figure was $332.3 million, up 37.64% from the prior year.
• Common Equity declined to $278.8 million in Q1 2026 per DFTX's latest filing, from $332.3 million in the prior quarter.
• Across five years, Common Equity topped out at $332.3 million in Q4 2025 and bottomed at $78.1 million in Q4 2023.
• Historically, Common Equity has averaged $178.1 million across 5 years, with a median of $153.6 million in 2022.
• Annual changes were most pronounced in 2024 — Common Equity surged 209.02% — and 2025, when it sank 50.19%.
• Definium Therapeutics' Common Equity stood at $150.9 million in 2022, then slumped by 48.23% to $78.1 million in 2023, then soared by 209.02% to $241.4 million in 2024, then jumped by 37.64% to $332.3 million in 2025, then dropped by 16.09% to $278.8 million in 2026.
• Business Quant data shows DFTX's Common Equity at $278.8 million in Q1 2026, $332.3 million in Q4 2025, and $130.6 million in Q3 2025.